ORGANIC LETTERS

2012
Vol. 14, No. 3
756–759

Remote Stereocontrol in [3,3]-Sigmatropic Rearrangements: Application to the Total Synthesis of the Immunosuppressant Mycestericin G

Nathan W. G. Fairhurst,[†] Mary F. Mahon,[†] Rachel H. Munday,[‡] and David R. Carbery*,[†]

Department of Chemistry, University of Bath, Bath, BA2 7AY, United Kingdom, and AstraZeneca R&D, Charnwood, Bakewell Road, Loughborough LE11 5RH, United Kingdom

d.carbery@bath.ac.uk

Received December 9, 2011

ABSTRACT



The Ireland–Claisen [3,3]-sigmatropic rearrangement has been used to access biologically important β,β′-dihydroxy α-amino acids. The rearrangement reported is highly stereoselective and offers excellent levels of remote stereocontrol. This strategy has been used to synthesize the natural immunosuppressant mycestericin G and *ent*-mycestericin G, allowing for a revision of absolute configuration of this natural product.

The realization that naturally occurring immunosuppressants, such as cyclosporin A,[1] greatly reduce the likelihood of host rejection has made human organ transplantation a viable medical process.[2] Arguably, this medical advance has profoundly changed society with heart, kidney, lung, liver, and bone-marrow transplants now being routinely successful. A large range of natural products have now been demonstrated to possess immunosuppressive activity[3] with recently reported examples seeking to improve biological activity or diminish side effects. One of the most potent immunosuppressant natural products is myriocin (**1**, Figure 1) which has been isolated from three different fungal sources.[4−6] Impressively, myriocin displays a 10–100-fold increase in immunosuppressant potency compared with cyclosporin A.[6]



Figure 1. Myriocin and β,β′-dihydroxy α-amino acids.

Structure–activity studies have strongly suggested the crucial structural feature of **1** with respect to biological activity is the polar β,β′-dihydroxy α-amino acid head group.[7] Accordingly, flexible and efficient synthetic entries to such β,β′-dihydroxy α-amino acids[8] (**2**, Figure 1) are

[†] University of Bath.
[‡] AstraZeneca R&D.

(1) Petcher, T. J.; Weber, H.-P.; Rüegger, A. *Helv. Chim. Acta* **1976**, *59*, 1480.

(2) (a) Calne, R. Y.; White, D. J. G.; Thiru, S.; Evans, D. B.; McMaster, P.; Dunn, D. C.; Craddock, G. N.; Pentlow, B. D.; Rolles, K. *Lancet* **1978**, 1323. (b) Powles, R. L.; Barrett, H.; Clink, H. E.; Kay, H. E. M.; Sloane, J.; McElwain, T. J. *Lancet* **1978**, 1327.

(3) Mann, J. *Nat. Prod. Rep.* **2001**, *18*, 417.

(4) (a) Kluepfel, D.; Bagli, J.; Baker, H.; Charest, M.-P.; Kudelski, A.; Sehgal, S. N.; Vezina, C. *J. Antibiot.* **1972**, *25*, 109. (b) Bagli, J.; Kluepful, D.; St-Jacques, M. *J. Org. Chem.* **1973**, *38*, 1253. (c) Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y.; Okumoto, T. *J. Antibiot.* **1994**, *47*, 208.

(5) Aragozzini, F.; Manachini, P. L.; Craveri, R.; Rindone, R.; Scolastico, C. *Tetrahedron* **1972**, *13*, 5493. (b) Destro, R.; Colombo, A. *J. Chem. Soc., Perkin Trans. 2* **1979**, 896.

(6) Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y.; Okumoto, T. *J. Antibiot.* **1994**, *47*, 208.

10.1021/ol203300k
Published on Web 01/12/2012

potentially important for the discovery of new immunosuppressive treatments and related chemical biology studies.[9] In addition, the structurally related natural products, sphingofungin E[10] and mycestericins A–G,[11] contain this key β,β'-dihydroxy α-amino acid moiety, and high levels of immunosuppressant activity have also been noted for both molecules.[12]

In recent years, we have been developing a program of research directed toward the synthesis of novel amino acids through Ireland–Claisen rearrangements of substrates rich in heteroatom substitution.[13] The Ireland–Claisen [3,3]-sigmatropic rearrangement is a key C–C bond forming reaction used in modern organic synthesis[14,15] and is therefore ideally suited to such research efforts. The rearrangement offers predictable diastereocontrol, chirality transfer, and the ability to form congested quaternary stereocenters. These three key attributes stem from the preference of acyclic substrates to rearrange *via* a highly ordered chair transition state.

Complex serine congeners, suitable for further elaboration to the natural product classes discussed above, might become accessible through sigmatropic rearrangements on serine-derived silylketene acetals. The employment of an Ireland–Claisen strategy for the synthesis of substituted serine analogues would require the generation of an unstable serine enolate. To avert this anticipated synthetic problem, the use of a serine-derived oxazolidine has been considered. Such a strategy would not only protect the sensitive β-hydroxy by circumventing degradative E1Cb elimination[16] but also offer the potential to control absolute stereochemistry *via* the chiral relay strategy pioneered by Seebach.[17] To examine this proposal, model ester substrate **3a** was readily synthesized[18] and subjected to standard Ireland–Claisen conditions used in our laboratory.[13]

On treatment with LiHMDS and Me_3SiCl at −78 °C, the silylketene acetal derived from methyl enol ether **3a** was found to rearrange smoothly, after warming to rt, with β-methoxy product **4a** isolated as a single stereoisomer in 78% yield (Table 1, entry 1). The stereoselectivity is notable, not only for its magnitude but also because the controlling stereocenter is two atoms from the forming

Table 1. Ireland–Claisen Rearrangement of Oxazolidine Enol Ether Substrates



entry	3	R	4	yield (%)	dr[a]
1	**3a**	Me	**4a**	78	>98:2
2	**3b**	Et	**4b**	84	>98:2
3	**3c**	^{i}Pr	**4c**	70	>98:2
4	**3d**	allyl	**4d**	71	>98:2
5	**3e**	propargyl	**4e**	76[b]	>98:2
6	**3f**	Ph	**4f**	77	>98:2
7	**3g**	PMP	**4g**	68	>98:2
8	**3h**	p-$CF_3C_6H_4$	**4h**	73	>98:2
9	**3i**	o-IC_6H_4	**4i**	58	>98:2
10	**3j**	Bn	**4j**	73	>98:2
11	**3k**	PMB	**4k**	75	>98:2
12	**3l**	o-I-Bn	**4l**	51[c]	>98:2
13	**3m**	^{i}Bu	**4m**	55[c]	>98:2
14	**3n**	Cy	**4n**	47[c]	>98:2

[a] Diastereomeric ratio stated as *syn*/*anti*. Measured by ^{1}H NMR (500 MHz) analysis of crude reaction mixture. [b] Isolated as TMS alkyne. [c] Reaction conducted on unpurified substrates **3l**–**n**.

(7) For leading references to structure–activity relationships with respect to **1** and the design of synthetic analogues, see: Kiuchi, M.; Adachi, K.; Kohara, T.; Minoguchi, M.; Hanano, T.; Aoki, Y.; Mishina, T.; Arita, M.; Nakao, N.; Ohtsuki, M.; Hoshino, Y.; Teshima, K.; Chiba, K.; Sasaki, S.; Fujita, T. *J. Med. Chem.* **2000**, *43*, 2946.

(8) For reviews concerning the synthesis of natural products containing β,β'-dihydroxy α-amino acids, see: (a) Ohfune, Y.; Shinada, T. *Eur. J. Org. Chem.* **2005**, 5127. (b) Kang, S. H.; Kang, S. Y.; Lee, H-S; Buglass, A. J. *Chem. Rev.* **2005**, *105*, 4537.

(9) (a) Miyake, Y.; Kozutsumi, Y.; Nakamura, S.; Fujita, T.; Kawasaki, T. *Biochem. Biophys. Res. Commun.* **1995**, *211*, 396. (b) Chen, J. K.; Lane, W. S.; Schreiber, S. L. *Chem. Biol.* **1999**, *6*, 221.

(10) Horn, W. S.; Smith, T. L.; Bills, G. F.; Raghoobar, S. F.; Helms, G. L.; Kurts, M. B.; Marrinan, J. A.; Frommer, B. R.; Thornton, R. A.; Mandara, S. M. *J. Antibiot.* **1992**, *45*, 1692.

(11) (a) Sasaki, S.; Hashimoto, R.; Kiuchi, M.; Inoue, K.; Ikumoto, T.; Hirose, R.; Chiba, K.; Hoshino, Y.; Okumoto, T.; Fujita, T. *J. Antibiot.* **1994**, *47*, 420. (b) Fujita, T.; Hamamichi, N.; Kiuchi, M.; Matsuzaki, T.; Kitao, Y.; Inoue, K.; Hirose, R.; Yoneta, M.; Sasaki, S.; Chiba, K. *J. Antibiot.* **1996**, *49*, 846.

(12) For selected recent syntheses of pertinent sphingolipid immunosuppressant natural products, see: (a) Jones, M. C.; Marsden, S. P. *Org. Lett.* **2008**, *10*, 4125. (b) Lee, K.-Y.; Oh, C.-Y.; Kim, Y.-H.; Joo, J.-E.; Ham, W.-H. *Tetrahedron Lett.* **2002**, *43*, 9361. (c) Gan, F.-F.; Yang, S.-B.; Luo, Y.-C.; Yang, W.-B.; Xu, P.-F. *J. Org. Chem.* **2010**, *75*, 2737. (d) Wang, B.; Lin, G.-Q. *Eur. J. Org. Chem.* **2009**, 5038. (e) Li, M.; Wu, A. *Synlett* **2006**, 2985. (f) Yamanaka, H.; Sato, K.; Sato, H.; Iida, M.; Oishi, T.; Chida, N. *Tetrahedron* **2009**, *65*, 9188. (g) Oishi, T.; Ando, K.; Inomiya, K.; Sato, H.; Hideyuki, I.; Ida, M.; Chida, N. *Bull. Chem. Soc. Jpn.* **2002**, *75*, 1927. (h) Oishi, T.; Ando, K.; Chida, N. *Chem. Commun.* **2001**, 1932. (i) Berhal, F.; Takechi, S.; Kumagai, N.; Shibasaki, M. *Chem.—Eur. J.* **2011**, *17*, 1915.

(13) (a) Tellam, J. P.; Kociok-Köhn, G.; Carbery, D. R. *Org. Lett.* **2008**, *10*, 5199. (b) Tellam, J. P.; Carbery, D. R. *J. Org. Chem.* **2010**, *75*, 7491. (c) Tellam, J. P.; Carbery, D. R. *Tetrahedron Lett.* **2011**, *52*, 6027. (d) Ylioja, P. M.; Mosley, A. D.; Charlot, C. E.; Carbery, D. R. *Tetrahedron Lett.* **2008**, *49*, 1111. (e) Harker, W. R. R.; Carswell, E. L.; Carbery, D. R. *Org. Lett.* **2010**, *12*, 3712. (f) Harker, W. R. R.; Carswell, E. L.; Carbery, D. R. *Org. Biomol. Chem.* **2012**10.1039/C2OB06853B.

(14) (a) Ireland, R. E.; Mueller, R. H. *J. Am. Chem. Soc.* **1972**, *94*, 5897. (b) Ireland, R. E.; Mueller, R. H.; Willard, A. K. *J. Am. Chem. Soc.* **1976**, *98*, 2868. (c) Ireland, R. E.; Wipf, P.; Armstrong, J. D., III. *J. Org. Chem.* **1991**, *56*, 650. (d) Ireland, R. E.; Wipf, P.; Xiang, J. N. *J. Org. Chem.* **1991**, *56*, 3572.

(15) For reviews concerning the Ireland–Claisen rearrangement, see: (a) Castro, A. M. *Chem. Rev.* **2004**, *104*, 2939. (b) Chai, Y. H.; Hong, S. P.; Lindsay, H. A.; McFarland, C.; McIntosh, M. C. *Tetrahedron* **2002**, *58*, 2905. (c) McFarland, C. M.; McIntosh, M. C. *The Claisen Rearrangement*; Hiersemann, M. N., Nubbemeyer, U., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2007; p 117. (d) Wipf, P. *Claisen Rearrangements; Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Paquette, L. A., Eds.; Pergamon: Oxford, 1991; Vol. 5, p 827. (e) Ilardi, E. A.; Stivala, C. E.; Zakarian, A. *Chem. Soc. Rev.* **2009**, *38*, 3133.

(16) For examples of Ireland–Claisen rearrangements in natural product synthesis using substrates bearing cyclic β-ethereal oxygen centers, see: (a) Ireland, R. E.; Armstrong, J. D.; Lebreton, J.; Meissner, R. S.; Rizzacassa, M. A. *J. Am. Chem. Soc.* **1993**, *115*, 7152. (b) Bunte, J. O.; Cuzzupe, A. N.; Daly, A. M.; Rizzacasa, M. A. *Angew. Chem., Int. Ed.* **2006**, *45*, 6376.

(17) (a) Seebach, D.; Aebi, J. D. *Tetrahedron Lett.* **1984**, *25*, 2545. (b) For a review of the self-regeneration chirality strategy, see: Seebach, D.; Sting, A. R.; Hoffmann, M. *Angew. Chem., Int. Ed. Engl.* **1996**, *35*, 2708.

(18) See Supporting Information for details of substrate synthesis.

C–C bond. This stereocontrol strategy has previously shown limited efficacy in asymmetric synthesis.[14,19]

The Ireland–Claisen rearrangement reaction of enol ethers **3a**–**n** is general and leads to the formation of β-alkoxy and β-aryloxy α-amino acid products, isolated as methyl esters **4a**–**n** in good yield and excellent diastereoselectivity. The absolute and relative stereochemistry has been confirmed by XRD of iodoaryl ether **4i** (Figure 2).



Figure 2. ORTEP plot of XRD analysis of **4i** (at 30% probability). Structure deposited with CCDC (CCDC 812147) and proposed Ireland–Claisen rearrangement geometry **I**.

The observed sense of stereoselectivity is consistent with transition state geometry **I** (Figure 2) whereby the enol ether fragment approaches the silylketene acetal *anti* to the oxazolidine *tert*-butyl group and agrees with reported stereoselective transformations using this regeneration of stereocenters tactic.[20] Notably, the rearrangement of substrates bearing *O*-functional handles (entries 4–5, 9, 13) and *O*-protecting groups (entries 4, 7, 10, 12) suggests that this strategy may be of future synthetic value. This sigmatropic transformation is highly stereoselective in each case. In three instances, however, the substrate proved to be particularly unstable, necessitating it being used without purification for conversion to the rearranged allylic ether products in yields of 47–55% over two steps (entries 13–15). It is unclear exactly why these substrates have proven to be so sensitive. However, we can speculate that the substantial steric bulk of these alkyl groups (*o*-iodobenzyl, ^{i}butyl, and cyclohexyl) promotes a conformational restriction of the enol ether oxygen, improving O_n donation into the enol ether π-system, ultimately leading to increased sensitivity. However, it was found that these systems rearrange as efficiently as that seen in entries 1–12 (70–80%), when the yield of ester formation is taken into account. The Ireland–Claisen rearrangement products **4a**–**n** are equivalent to *O*-alkyl and *O*-aryl aldols, and when placed in this context, the power of this rearrangement becomes apparent. Low levels of diastereoselectivity (dr ≤2:1) are observed when serine-derived oxazolidine esters are used in aldol reactions in conjunction with simple achiral aldehydes.[21]

The rearrangement is amenable to streamlined preparative scale (4 mmol of **6**) manipulations. For example, when EDCI mediated coupling of **5**[22] and **6**,[12a] Ireland–Claisen rearrangement, and carboxyl benzylation are conducted without intermediate purification, **7** is isolated in 81% yield over three steps (Scheme 1).

Scheme 1. Preparative Scale Rearrangement



This rearrangement reaction offers a rapid access to complex and functionalized β,β'-dihydroxy α-amino acid motifs. To demonstrate the synthetic potential, a synthesis of mycestericin G (**8**, Scheme 2) has been examined. This natural product features a polyhydroxy α-amino acid head group and a lipophilic tail, offering a potential entry from the cross-metathesis union of a rearrangement product **7** and a suitable lipophilic olefin partner, such as **9** (Scheme 2). Our envisioned strategy was to examine olefin homodimer **9**[23] in combination with the second generation Hoveyda–Grubbs Ru-carbene catalyst,[24] as Grubbs has previously demonstrated the improved performance of homodimers[25] and the stated catalyst in sterically congested allylic alcohols[26] in cross-metathesis reactions.

Scheme 2. Mycestericin G Synthetic Strategy



(19) A chiral glycinate has offered a dr of 11:1 in an Ireland–Claisen rearrangement; see: (a) Matsui, S.; Oka, N.; Hashimoto, Y.; Saigo, K. *Enantiomer* **2000**, *5*, 105. Other examples with poor levels (dr ≤ 3:1) of remote diastereocontrol, see: (b) Kallmerten, J.; Gould, T. J. *J. Org. Chem.* **1986**, *51*, 1152. (c) Shu, A. Y. L.; Djerassi, C. *J. Chem. Soc., Perkin Trans. 1* **1987**, 1291.

(20) For incipient C–C bond formation *anti* to the oxazolidine *tert*-butyl group, see: (a) Seebach, D.; Aebi, J. D.; Gander-Coquoz, M.; Naef, R. *Helv. Chim. Acta* **1987**, *70*, 1194. (b) Zhang, J.; Flippen-Anderson, J. L.; Kozikowski, A. P. *J. Org. Chem.* **2001**, *66*, 7555. (c) Brunner, M.; Saarenketo, P.; Straub, T.; Rissanen, K.; Koskinen, A. M. P. *Eur. J. Org. Chem.* **2004**, 3879. (d) Brunner, M.; Nissinen, M.; Rissanen, K.; Straub, T.; Koskinen, A. M. P. *J. Mol. Struct.* **2005**, *734*, 177. (e) Ling, T.; Macherla, V. R.; Manam, R. R.; McArthur, K. A.; Potts, B. C. M. *Org. Lett.* **2007**, *9*, 2289. (f) Ling, T.; Potts, B. C.; Macherla, V. R. *J. Org. Chem.* **2010**, *75*, 3882.

(21) Brunner, M.; Koskinen, A. M. P. *Tetrahedron Lett.* **2004**, *45*, 3063.

(22) Ghosez, L.; Yang, G.; Cagnon, J. R.; Le Bideau, F.; Marchand-Brynaert, J. *Tetrahedron* **2004**, *60*, 7591.

(23) Scheiper, B.; Bonnekessel, M.; Krause, H.; Fürstner, A. *J. Org. Chem.* **2004**, *69*, 3943. See Supporting Information for full details.

(24) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2000**, *122*, 8168.

(25) Blackwell, H. E.; O'Leary, D. J.; Chatterjee, A. K.; Washenfelder, R. A.; Bussmann, D. A.; Grubbs, R. H. *J. Am. Chem. Soc.* **2000**, *122*, 58.

The synthesis of mycestericin G was completed after PMB deprotection of **7**, cross metathesis, and hydrogenation, with final *N*-Boc oxazolidine cleavage furnishing mycestericin G after chromatography. The ^{1}H NMR data were in excellent agreement with those reported, but the optical rotation was opposite in sign, yet of a similar magnitude, to that quoted (Scheme 3). In contrast, the parallel synthetic sequence from L-serine produced *ent*-**8**, now with the same sense of optical rotation and comparable magnitude to that reported for mycestericin G.

Scheme 3. Total Synthesis of Mycestericin G



To explain this discrepancy, we offer the following analysis. Hydrogenation of **1** forms dihydromyriocin **10** (Figure 3).[27] Key is the realization that hydrogenation of the seemingly innocuous olefin in **1** leads to a reversal in the sense of optical rotation; i.e., myriocin **1** is dextrorotatory while **10** is levorotatory.

The absolute configuration of mycesterin E (**11**) has been determined through the total synthesis.[28] This report also demonstrated that mycestericin G (**8**) was obtained from synthetic **11**, forming material which was observed to have identical spectroscopic data. However, no optical rotation data were reported for this *synthetic* mycestericin G. Therefore, there is no unequivocal demonstration that the configuration of the stereocenters in mycestericin E is the same as the two stereocenters in mycestricin G. The recent elegant synthesis of mycestericin G by Kumagai and Shibasaki is of particular interest.[12i] This effort resulted in the synthesis of the structure originally reported, however, with an opposite sense of optical rotation to that in the original isolation paper. We feel that this observation offers further credence to a reassignment of configuration of the natural immunosuppressant mycestericin G.



Figure 3. Effect of alkene on sense of optical rotation.

In conclusion, an Ireland–Claisen route to polyhydroxyamino acids, using a self-regeneration of stereocenters strategy, has been developed. It has also been applied in a succinct synthesis of mycestericin G and *ent*-mycestericin G, allowing a reassignment of configuration of this immunosuppressant natural product.

Acknowledgment. We thank The University of Bath, EPSRC, and AstraZeneca for studentship funding (NWGF).

Supporting Information Available. Full experimental details and data for all novel compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

(26) Sterically demanding allylic alcohols have displayed efficacy in cross-metathesis reactions using Hoveyda–Grubbs II metathesis catalysts; see: Stewart, I. C.; Douglas, C. J.; Grubbs, R. H. *Org. Lett.* **2008**, *10*, 441.

(27) Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Yoneta, M.; Chiba, K.; Hosshino, Y.; Okumoto, T. *J. Antibiot.* **1994**, *47*, 216.

(28) Fujita, T.; Hamamichi, Y.; Matsusaki, T.; Kitao, Y.; Kiuchi, M.; Node, M.; Hirose, R. *Tetrahedron Lett.* **1995**, *36*, 8599.